BC Partners' Aenova acquires Haupt Pharma Gruppe

BC Partners provided new financing for the acquisition, alongside a €130m debt package.

BC Partners acquired Aenova for €480m from Bridgepoint in 2012. JP Morgan provided debt financing for the transaction, with leverage accounting for around 50% of the deal value.

At the time of the acquisition, the GP planned to grow the firm organically and through bolt-ons. Moreover, BC Partners and Aenova talked about plans to float the company on the stock market in the next five years, with further acquisitions planned in the next 12-18 months, in April this year.

Aenova acquired fellow pharmaceutical companies Euro Vital Pharma and Temmler Group in 2012.

Aenova was initally founded in 2008, when Bridgepoint merged two of its portfolio companies: Swiss Caps (acquired in 2005) and Dragenopharm (acquired in 2007).

The business, which develops, manufactures and provides marketing services for medicinal products and dietary supplements, reported a turnover of €500m in 2012. Its headquarters are in Pähl, near Munich.

Company
Haupt Pharma produces pharmaceutical products. The firm has offices in Germany, France, Italy, the US and Japan, across which the firm employs around 2,500 staff. It was founded in 1937 under the name Heinz Haupt chem-pharm Fabrik in Berlin. Haupt Pharma Gruppe is now headquartered in Wolfratshausen.

In 2008, Haupt Pharma bought fellow pharmaceutical businesses Wülfing Pharma and Amareg. In 2009, the firm acquired a production plant in Italy from US pharma Pfizer.

The firm reported a turnover of €282m in 2012.

People
Karl Heinz Brücher is COO of Haupt Pharma. Heiner Hoppmann is Aenova's CEO. Stefan Zuschke and Michael Wunderlich were responsible for BC Partners' original deal in Aenova.

Adviser
Equity – CMS Hasche Sigle (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany
• BC Partners
• Acquisition finance